BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Amgen opens its next-generation workplace in Singapore

May 15, 2018 | News

Leading new ways of workplace collaboration and connection to enhance innovation, productivity and workplace culture for an agile workplace



Singapore- Amgen announced the official opening of its new manufacturing support office – the NextGen Workplace that is designed to inspire innovation and collaboration, enhance productivity and to build a vibrant work culture to support its growth in Singapore. Located at Tuas Biomedical Hub and spanning more than 7,500 square meters, the NextGen Workplace will support both Amgen's revolutionary NextGen Biomanufacturing and its Chemical Synthesis manufacturing facilities. Amgen has now invested more than SGD$400 million into its Singapore operations.

Amgen's NextGen Workplace will play a pivotal role in attracting and retaining talented staff. Boasting various collaboration spaces that encapsulate Amgen's brand values, the new workplace engages employees with highly flexible activity-based work options to drive faster decisions, foster greater exploration of ideas and connect colleagues while integrating social spaces for employees to recharge.

"At Amgen, our aim is to always groom a future-ready workforce to transform the promise of science and biotechnology into therapies that fulfil our mission to serve patients around the world. Amgen's NextGen Workplace in Singapore marks an important milestone in our ongoing journey to become more agile and patient-focused. This new workspace and our complementary work policies not only enhance our productivity and the way we work but will also support our efforts to create a workspace that is open, empowering and encourage collaboration," said Arleen Paulino, Vice President, Site Operations at Amgen Singapore Manufacturing.

"The expansion of Amgen's local footprint is testament to Singapore's strong track record for best-in-class pharmaceutical manufacturing. Singapore continues to see companies such as Amgen build on their existing presence here to manufacture new pharmaceutical products and adopt new manufacturing technologies. EDB remains committed to supporting the continued growth and talent development of the sector, to create good business and jobs opportunities," said Ms. Ho Weng Si, Director, Biomedical Sciences, Singapore Economic Development Board.

Ms Ho also congratulated Amgen on its agile approach towards the future of work as seen in its NextGen Workplace, which is aligned with Singapore’s continued push for innovation and productivity.